Experimental liver shot aims to wake up immune system against colorectal cancer

NCT ID NCT07172282

Recruiting now Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether a drug called Nelitolimod, given directly into the liver through a special catheter, can safely boost the immune system in 10 people with colorectal cancer that has spread to the liver. Participants will receive the drug three times before their planned liver surgery. The main goal is to see if this approach is feasible and safe, not yet to prove it works against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nelitolimod
What this could lead to: If this works, it could point toward a new way to boost the immune system against colorectal cancer that has spread to the liver, potentially making surgery more effective.
What could go wrong: This is a very early, small study with only 10 people. It is designed mainly to check safety and feasibility, not to prove the treatment works. The drug may not produce a meaningful immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

RJ Zuckerberg
RECRUITING

Lake Success, New York, 11042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.